Bionano Genomics, Inc.: CVI Investments, Inc. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
CVI Investments, Inc. filed an amended Schedule 13G with the SEC disclosing a change in its beneficial ownership stake in Bionano Genomics, Inc. (accession number 0001649553-26-000141). The filing updates the investment firm's previously reported position in the genomics company, though the amended document's headline disclosure did not specify the revised share count or percentage. The amendment matters because 13G updates signal shifts in passive or institutional ownership that can influence Bionano's shareholder base and governance dynamics. Investors will watch for the full filing details to confirm CVI's current stake size and whether the change reflects accumulation or reduction.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
CVI Investments, Inc., Bionano Genomics, Inc.